- Home
- CLRO vs MDCX Comparison
CLRO vs MDCX Comparison
Compare CLRO & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLRO | MDCX |
|---|---|---|
| Founded | 1983 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.3M | 15.9M |
| IPO Year | 2018 | 2025 |
Fundamental Metrics
Financial Performance| Metric | CLRO | MDCX |
|---|---|---|
| Price | $4.58 | $0.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 28.5K | ★ 5.0M |
| Earning Date | 05-18-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $46,067,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 11.59 | N/A |
| 52 Week Low | $2.71 | $0.15 |
| 52 Week High | $16.50 | $3.05 |
Technical Indicators
Market Signals| Indicator | CLRO | MDCX |
|---|---|---|
| Relative Strength Index (RSI) | 45.41 | 26.53 |
| Support Level | $4.66 | $0.15 |
| Resistance Level | $5.40 | $0.36 |
| Average True Range (ATR) | 0.26 | 0.02 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 9.87 | 5.65 |
Price Performance
Historical ComparisonAbout CLRO ClearOne Inc. (DE)
ClearOne Inc is currently engaged in activities that consist solely of fulfilling warranty and technical support obligations on legacy products, evaluating potential Strategic Transactions, managing and liquidating remaining assets of the company's legacy operating business, collecting accounts receivable and recovering prepaid assets, satisfying outstanding liabilities, and maintaining public-company compliance.
About MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.